Atopic Dermatitis

A comparative assessment shows children with psoriasis have a four-fold increased risk of reaching PASI 75 with biologics.

The FDA will rule on the type 2 inflammation-targeting biologic for another indication this May.

New findings show a greater risk of longer, more persistent cases of atopic dermatitis among children with mothers suffering from depression.

A certified physician assistant breaks down how dermatology specialty demand has influenced the modern care team.

How primary care fits into the scheme of patient management, and what new therapies may mean for atopic dermatitis.

Nearly one dozen therapies have reached the psoriasis market, and the new standard is at least 90% skin clearance—an achievement previously unmet.

Distinguishing biologic-eligible patients may still need further biomarker and disease severity research.

How the annual college meeting has come to address the rapidly developing field of immunotherapy.

The pivotal phase 3 findings are the largest to assess a systemic pediatric atopic dermatitis treatment, to date.

New findings from the 12-week pivotal JADE MONO-1 trial show the JAK1 inhibitor's benefit in skin clearance and itch relief.

The data presented at the EADV Congress in Madrid builds on the findings reported at 52 and 64 weeks in the phase 3 reSURFACE 1 and 2 trials.